Nasdaq to Suspend KaloBios Pharmaceuticals, Inc. on January 13, 2016

NEW YORK, Jan. 12, 2016 - The Nasdaq Stock Market (“Nasdaq”) announced today that, pursuant to Listing Rule 5815(a)(1)(B), KaloBios Pharmaceuticals, Inc. (Nasdaq:KBIO) will be suspended from Nasdaq effective January 13, 2016.

Trading in the Company’s securities has been halted since December 17, 2015. The trading halt will no longer be in effect upon the suspension of KaloBios from Nasdaq, which would allow the Company’s securities to be eligible for trading in the over-the-counter markets under the symbol “KBIOQ.”

A hearing is scheduled for February 25, 2016, to review the company’s appeal of Nasdaq’s December 18, 2015 delist determination.

For news and additional information about the Company, including whether the Company’s securities will trade on another venue, please review the Company’s public filings or contact the Company directly.

For more information about Nasdaq trade halts, visit www.nasdaqtrader.com. For more information about the Nasdaq delisting process, visit listingcenter.nasdaq.com.

About Nasdaq:

Nasdaq (Nasdaq:NDAQ) is a leading provider of trading, clearing, exchange technology, listing, information and public company services across six continents. Through its diverse portfolio of solutions, Nasdaq enables customers to plan, optimize and execute their business vision with confidence, using proven technologies that provide transparency and insight for navigating today's global capital markets. As the creator of the world's first electronic stock market, its technology powers more than 70 marketplaces in 50 countries, and 1 in 10 of the world's securities transactions. Nasdaq is home to more than 3,600 listed companies with a market value of approximately $8.8 trillion and more than 10,000 corporate clients. To learn more, visit: nasdaq.com/ambition or business.nasdaq.com.